Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 2/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155179 | 1.00 | PDK2 (0.47) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL25155491 | 0.97 | PDK2 (0.49) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL30344073 | 0.97 | PDK2 (0.49) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL25155930 | 0.88 | PDK2 (0.47) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL31359914 | 0.88 | PDK2 (0.47) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL30344146 | 0.88 | PDK2 (0.47) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL25155451 | 0.87 | KDM4E (0.47) | PDK2 | |
| SCHEMBL30344711 | 0.87 | KDM4E (0.47) | PDK2 | |
| SCHEMBL25155891 | 0.87 | HTR1D (0.40) | PDK2 | |
| SCHEMBL30344152 | 0.87 | HTR1D (0.40) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | PDK2 3215/4885CA12 697/4885CA1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.